Utility of Fibroscan XL to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery | Scientific Reports
Frontiers | Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment
Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis - eClinicalMedicine
FibroScan - Because liver health matters
Frontiers | Validation of Controlled Attenuation Parameter Measured by FibroScan as a Novel Surrogate Marker for the Evaluation of Metabolic Derangement
PDF) FibroScan-AST Score Predicts 30-Day Mortality or Need for Mechanical Ventilation among Patients Hospitalized with COVID-19
Clinical and Molecular Hepatology
Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis - eClinicalMedicine
Individual patient data meta-analysis of controlled attenuation parameter ( CAP) technology for assessing steatosis - ScienceDirect
FibroScan - Because liver health matters
Frontiers | Liver Steatosis: Better Predictor of CKD in MAFLD Than Liver Fibrosis as Determined by Transient Elastography With Controlled Attenuation Parameter
Non-invasive tests of non-alcoholic fatty liver disease | Chinese Medical Journal
General Brochure_FibroScan_EN
Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease
A prospective 5-year study on the use of transient elastography to monitor the improvement of non-alcoholic fatty liver disease following bariatric surgery | Scientific Reports
Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study
Presentación de PowerPoint
Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter - ScienceDirect
FibroScan - Because liver health matters
KoreaMed Synapse
Frontiers | Validation of Controlled Attenuation Parameter Measured by FibroScan as a Novel Surrogate Marker for the Evaluation of Metabolic Derangement
Clinical and Molecular Hepatology
Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease - ScienceDirect
